Processing. Please wait.



  • All Tracks
  • The Great Hall
  • Aston Webb Reception
  • Elgar Concert Hall
  • G30
  • G31
1570780800 - 1570780800
The Great Hall
1570781700 - 1570785900
The Great Hall
1570786200 - 1570787100
The Great Hall
1570787100 - 1570788900

BioLearn Masterclass: How the Drug Discovery Industry Works

This Masterclass will cover a brief overview of the following topics in a small group training-session:
  • The commercial landscape
  • Human biology, pathology and drug targets
  • Drug discovery and development
  • Industry pressures and responses
  • Industry in transition
1570788900 - 1570790700

BioLearn Masterclass: Presentation Skills for Scientists

This Masterclass will provide an overview the following topics in a small-group training session:
  • Nervousness and voice control
  • Verbal scientific delivery and communications
  • Slide content and quality
1570789800 - 1570792500
Elgar Concert Hall

Panel: Going to America?

The US Healthcare market is valued at more than $2.8 Trillion and is frequently the number one priority for UK / Europe life sciences companies looking to expand their international presence and set up foreign subsidiaries. A US presence also facilitates the access to the US investment and capital markets, and the downstream opportunity to IPO via the Nasdaq equity market.

Whilst there are many similarities in business approach and language, there are also significant cultural and legal differences which can catch out the unwary when seeking to establish and operate a local entity.
Expanding into new markets, geographies, and market segments can be immensely rewarding but also challenging if approached without adequate preparation, knowledge and support. Companies need to think strategically about which avenues they need to explore to develop realistic market access strategies that create the opportunity for growth and long-term value creation.

Our expert panel will provide well informed advice as to how best to approach establishing a North American entity and develop practical strategies and plans to optimise operations, organisational structures, financials and processes across the life sciences value chain to maximise their chances of business success in this dynamic healthcare market.

Our panel will offer advice on the following topics:

  • East, West, or Middle – are there areas more suitable for R&D or manufacturing operations?
  • Impact of time zones, access and travel
  • What are the varying incentives and taxation differences between States
  • FDA clearance and approval to obtain FDA certification
  • Risk management and insurance provisions to consider
  • Incorporation or branch legal structure?
  • Visas, relocation, tax, immigration issues
  • Differences in IP between the UK and US e.g. first to file vs first to invent
  • Understanding how the health system works
  • Access to investment, capital, grants and where to leverage practical setup support
  • Tips on recruiting & retaining local staff
  • Identifying and interacting with a new range of US out-source partners
  • Local networking and interaction with the community
1570792500 - 1570796100

'How To' Develop & Manage Your Corporate Reputation to Boost Value

A strong corporate reputation is a vital component of an organisation’s success, with financial analyst recommendations, CSR strategies, media exposure, industry collaborations and positive perceptions all helping to boost market value. Yet, many organisations ignore these aspects as they grapple with the more hard-edged, day-to-day urgencies – reputation is a long-term concept that is difficult to quantify.

One thing is certain, there is a high cost to pay for losing a good reputation and your good standing with stakeholders.  A smaller firm may be devastated by loss of reputation, so it pays to have a strategy in place outlining how you plan to build and manage your corporate reputation.

This ‘How To’ session will support you in doing just that, addressing the importance of positively promoting your organisation by highlighting your key assets; how to showcase your unique strengths when pitching for funding or entering into a collaboration, and the importance of understanding cultural communication differences when networking with investors and the wider industry. 

Our expert speakers will also cover:
  • Experience and information – how do others view you based on direct and indirect interaction?
  • Getting key stakeholders to perceive the company as credible, reliable, responsible and trustworthy
  • How do you develop a positive identity based on demonstrating consistent performance over a sustained period?
  • Leveraging stakeholder support for the firm in times of difficulty
  • Using reputation to generate sustained competitive advantage
  • The importance of key opinion leader endorsement
  • The role of social media in today's fast moving world
  • Managing your brand and ensure it is supported by stakeholder experience
  • In times of skill shortages, a good business reputation assists in employee recruitment, development and retention
  • Ethics – a firm that has an ethical reputation will engender positivity
My Schedule


Instinctif Partners
1570792500 - 1570793400
The Great Hall
1570796100 - 1570799700

'How To' Successfully Prepare for a Company Exit

When it comes to preparing for a company exit, there is no universal answer.  Founders want to sell for as much money as possible (so do investors) and buyers want to spend as little as possible, so both parties need to find alignment.

Investors capitalise a company with one objective in mind: to get a return on their investment.

So, whilst Venture Capitalists, business angels and other types of investors may not look for an exit in the first few years of a start-up, they will require some type of liquidity event to put cash on the table. Exits provide capital to start-up investors, which can then return the money to their limited partners (in the case of Venture Capitalists) or to the investors themselves (in the case of business angels). If the return is sufficiently robust, this may encourage further investment in additional, early-stage Life Sciences companies.

This ‘How To’ session will explore this fascinating, and for most companies, commercially essential aspect of their corporate progression covering all stages of company development, whether they be start-ups or more mature companies with a transaction in their business plan.

Our experts will provide a practical ‘How To’ guide on:
  • When is the right time to exit?
  • Trade sales: A buyer takes over the start-up using cash or stock as a compensation
  • Floatation / IPO: A company floats on a stock market, selling a significant number of their shares in the process to institutional and non-institutional investors. IPO's can provide large sums of capital to all parties involved (founders, early employees and investors)
  • When and why do IPO’s make sense?
  • Which exchanges are likely to yield the best performance: NASDAQ, AIM, Euronext and other markets are potential vehicles for floatation
  • What happens post-IPO?
  • How do you progress from a VC/PE based environment to more institutional investors?
  • Mergers & Acquisitions: These transactions can imply a merging with a similar but larger company or a merger of equals to create increased critical mass. Public companies that have suffered a technology failure but still have development cash represent good reverse targets
  • How to go about it -  Is there a role for advisers?
  • Go to market: Companies that can establish a solid business model and scale might choose to stay independent and reinvest the profits in the company whilst avoiding the public markets and the obligations that come with it
My Schedule